|
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Clinical research trials and Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer. Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer  Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
For Condition: Thyroid Cancer,Renal Cell Cancer,Kidney Cancer,Lung Cancer,Melanoma,Eye Cancer,Head and Neck Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Yale Cancer Center
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of indium In 111 pentetreotide in treating patients who have refractory cancer.
Details: OBJECTIVES: I. Determine the maximum tolerated dose (MTD), toxic effects, and the preliminary antitumor activity of indium In 111 pentetreotide. PROTOCOL OUTLINE: This is a dose escalation study. Patients receive indium In III pentetreotide (OctreoScan) IV on day 1. Imaging is conducted on days 3 and 6. Treatment continues weekly for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of at least 3 patients receive escalating doses of OctreoScan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose limiting toxicities. Patients are followed every 3 months for the first year, then every 6 months thereafter. PROJECTED ACCRUAL: Up to 35 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven malignancy with no alternate treatments available - Measurable or evaluable progressive disease - Somatostatin receptors present on tumor and uptake demonstrated on diagnostic scan with OctreoScan --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) - Endocrine therapy: Not specified - Radiotherapy: At least 4 weeks since prior wide field radiation therapy - Surgery: Recovery from prior surgery --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-2 - Life expectancy: At least 3 months - Hematopoietic: Platelet count at least 100,000/mm3; Absolute neutrophil count at least 1,500/mm3 - Hepatic: Total bilirubin no greater than 2.0 mg/dL - Renal: Creatinine clearance at least 40 mL/min - Other: No active infections; Not HIV positive; No coexisting medical condition; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JohnMurren, Study Chair, Yale Cancer Center
Yale Comprehensive Cancer Center
New Haven, Connecticut, 06520-8028
United States
Additional Information:
Study ID Numbers: CDR0000065414; YALE-HIC-9041,NCI-G97-1154
Study Start Date: July 2001
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002947
Other Lung Cancer Studies:
1. Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
2. Biological Therapy in Treating Patients With Metastatic Cancer
3. Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
Related Studies:
Other Lung Cancer Clinical Trials
Other Connecticut Clinical Trials
Other New Haven Clinical Trials
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
|
|
|
|
|
|
|
|
